Navigation Links
Edarbyclor (azilsartan medoxomil and chlorthalidone) Head-to-Head Data Published in Hypertension
Date:6/19/2012

DEERFIELD, Ill., June 19, 2012 /PRNewswire/ -- Results of a 12-week, head-to-head, phase 3 study published online in the American Heart Association journal Hypertension found systolic blood pressure (SBP) reductions of a fixed-dose combination of azilsartan medoxomil and chlorthalidone 40/25 mg were statistically superior to those of the fixed-dose combination of olmesartan medoxomil-hydrochlorothiazide 40/25 mg. This fixed-dose combination (azilsartan medoxomil and chlorthalidone) is currently marketed as Edarbyclor in the United States. It is the first and only hypertension medication to combine an angiotensin II receptor blocker (ARB) with chlorthalidone, a diuretic, in a once-daily, single tablet.

"Hypertension and its impact on cardiovascular health have long been studied; the goal of this particular study was to determine whether a fixed-dose combination of a well-established yet underutilized diuretic paired with a new angiotensin II receptor blocker would provide an effective option to help control hypertension," said study co-author Michael Weber, M.D., professor of medicine, State University of New York, Downstate College of Medicine, Brooklyn, N.Y. "The data showed that Edarbyclor exhibited superior blood pressure reductions compared to a commonly used combination treatment."

Results after 12 weeks of treatment showed that the fixed-dose combination of azilsartan medoxomil and chlorthalidone 40/25 mg reduced clinic SBP by 42.5 mm Hg from baseline. The reductions were statistically significantly (P<0.001) greater than that of the fixed-dose combination of olmesartan medoxomil-hydrochlorothiazide 40/25 mg (37.1 mm Hg). Similar results were observed across patient subgroups, including age, gender or race. Edarbyclor was approved by the U.S. Food and Drug Administration in December 2011 for the treatment of hypertension to lower blood pressure in adults.

"Takeda has a long history in exploring new approaches for the manageme
'/>"/>

SOURCE Takeda Pharmaceuticals U.S.A., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function
2. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
3. First targeted and programmable nanomedicine to show clinical antitumor effects published
4. Newly-Published Study Compares SURFAXIN LS™ and CUROSURF® in Well-Established Model of Respiratory Distress Syndrome
5. Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes for the ... system received a score of 0 (range -10 to +10) for its impact on ... Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several changes to ...
(Date:7/29/2015)... CITY , July 29, 2015 /PRNewswire/ - Aeterna ... today announced it has selected an optimized Erk ... milestone in the development of a new class ... MAPK pathway represents a prime target for therapeutic ... antitumor activities and survival benefits for B-Raf and ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi ... Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized in ... core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical Site ...
(Date:7/29/2015)... ... , ... Costello served as Lead Levee Design Engineering Manager for a feasibility ... area from future storm surge flooding, such as occurred in Hurricane Ike in 2008. ... for providing protection, Costello also balanced socio-economic and environmental needs and concerns. ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2
... CITY, Calif., Sept. 13 Abaxis, Inc.,(Nasdaq: ... analysis systems, announced today that Clint Severson, CEO ... LLC Sixth Annual San,Francisco Institutional Investor Forum Conference ... Time at The Ritz-Carlton Hotel in San Francisco. ...
... JOSE, Calif., Sept. 13 Micrus,Endovascular Corporation (Nasdaq: ... of Stockholders will be broadcast live over the,Internet on ... (9:00,a.m. Pacific time). Those listening to the meeting via ... ask questions during the,meeting. What: Micrus Endovascular ...
... Exchange Agreement, COPENHAGEN, September 13 Genmab ... asset exchange agreement with,Medarex, Inc. Under the terms ... HuMax-Inflam(TM)/MDX-018, which targets IL-8, and Medarex will,receive full ... and,Medarex will release to each other all previously ...
Cached Biology Technology:Micrus Endovascular to Webcast Fiscal 2007 Annual Meeting of Stockholders 2Genmab Announces Asset Exchange Agreement 2
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... University of Manchester scientists have discovered for the first time ... (HPV) triggers cancer in what could lead to new treatments ... to increase the risk of developing cancers of the cervix ... accounting for approximately 70% of all cervical cancer cases. ...
... , This release is available in Spanish ... Biology and Regenerative Medicine (CABIMER) and the University of ... apoptosis is not only essential in breast tumor cells resistance ... potential against cancer), but this protein is also key to ...
... NY - One big challenge in converting plants to biofuels ... up make it hard to break them down. Now scientists ... are unraveling details of how plant cells, structural supports - ... finding ways to change their composition for more efficient biofuel ...
Cached Biology News:Scientists identify how virus triggers cervical and mouth cancer 2A protein called cFLIP makes tumor cells in breast cancer resistant to treatments 2Scientists unravel more details of plant cell-wall construction 2
... System combines 2 products into 1:, , ... molecular isolation kit , ,The FastPrep ... and Qbiogene/BIO101 System Matrix and Isolation Kits. ... micro tubes eliminating the use of metal ...
... ,Each upright model provides fast pull-down, ... uniformity for refrigerated blood. The BBR25 and ... for complete blood storage monitoring. Models BBR6, ... the HemaPro 101 alarm/monitor. All of these ...
... form of Tobacco Etch Virus (TEV) protease ... significantly more stable than native TEV protease, ... recognizes a seven amino acid (Glu-Asn-Leu-Tyr-Phe-Gln-Gly, cleaving ... for removing affinity tags from fusion proteins ...
S-100A10 (H-80)...
Biology Products: